ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase and increased binding to biglycan
Anne Hiukka, Marcus Ståhlman, Camilla Pettersson, Malin Levin, Martin Adiels, Susanne Teneberg, Eeva S. Leinonen, Lillemor Mattsson Hultén, Olov Wiklund, Matej Orešič, Sven-Olof Olofsson, Marja-Riitta Taskinen, Kim Ekroos, Jan Borén (Corresponding Author)
Dive into the research topics of 'ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase and increased binding to biglycan'. Together they form a unique fingerprint.